Anna Åkesson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anna Åkesson has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Anders Christensson
Department of Clinical Sciences Lund University Malmö Sweden
2 shared publications - Anders Grubb
Department of Clinical Chemistry Skåne University Hospital Lund University Lund Sweden
2 shared publications - Anders Larsson
Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 75185 Uppsala, Sweden
2 shared publications - Anna Sjöström
Department of Nursing, Umea University, Umea, Sweden
2 shared publications - Arend Bökenkamp
Department of Pediatric Nephrology, Emma Childrens Hospital, Amsterdam, the Netherlands
2 shared publications - Carl Mikael Oberg
Lund University
2 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- p. 1-11
Identification of cystatin C as a new marker of glomerular filtration rate, and of shrunken pore syndrome – a new kidney disorder defining selective glomerular hypofiltration syndromes – calls for expansion of the international KDIGO guidelines
Cystatin C was identified as a marker of glomerular filtration rate (GFR) in 1979, and the parallel analysis of cystatin C and creatinine led to the identification of shrunken pore syndrome (SPS) - a new kidney disorder - in 2015. Since then, it has been shown that cystatin C in many aspects is superior to creatinine as a marker of GFR and cardiovascular risk. SPS, an entity within the selective glomerular hypofiltration syndromes (SGHS), has been demonstrated to be associated with a strong increase in morbidity and mortality in several populations. Despite the seriousness of SPS and SGHS, and the availability of potential treatments, many patients with these conditions remain undiagnosed, due to the limitations of the international Kidney Disease Improving Global Outcomes Organization (KDIGO) guidelines. Given the significant clinical advantages of cystatin C in diagnosing and treating kidney disorders, there is a need to expand the KDIGO guidelines to include cystatin C measurements alongside creatinine at least in the initial patient evaluation but also in follow-up evaluations. This would improve the early detection and management of patients with kidney diseases, ultimately enhancing patient outcomes. The present discourse summarizes the development of this understanding from the original observations in 1979 and 2015 to the latest findings.
- 1 September 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- p. 1-11
Open AccessIdentification of cystatin C as a new marker of glomerular filtration rate, and of shrunken pore syndrome – a new kidney disorder defining selective glomerular hypofiltration syndromes – calls for expansion of the international KDIGO guidelines
Cystatin C was identified as a marker of glomerular filtration rate (GFR) in 1979, and the parallel analysis of cystatin C and creatinine led to the identification of shrunken pore syndrome (SPS) - a new kidney disorder - in 2015. Since then, it has been shown that cystatin C in many aspects is superior to creatinine as a marker of GFR and cardiovascular risk. SPS, an entity within the selective glomerular hypofiltration syndromes (SGHS), has been demonstrated to be associated with a strong increase in morbidity and mortality in several populations. Despite the seriousness of SPS and SGHS, and the availability of potential treatments, many patients with these conditions remain undiagnosed, due to the limitations of the international Kidney Disease Improving Global Outcomes Organization (KDIGO) guidelines. Given the significant clinical advantages of cystatin C in diagnosing and treating kidney disorders, there is a need to expand the KDIGO guidelines to include cystatin C measurements alongside creatinine at least in the initial patient evaluation but also in follow-up evaluations. This would improve the early detection and management of patients with kidney diseases, ultimately enhancing patient outcomes. The present discourse summarizes the development of this understanding from the original observations in 1979 and 2015 to the latest findings.
- 1 July 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (1) , e233417
Assessing Digital Breast Tomosynthesis Impact on Early Cancer Detection: Insights from Consecutive Screening
Analysis of the Malmö Breast Tomosynthesis Screening Trial revealed lower cancer detection rates and invasive cancers after tomosynthesis, suggesting enhanced early detection potential, particularly for luminal A–like cancers.
- 1 July 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (1) , e233417
Assessing Digital Breast Tomosynthesis Impact on Early Cancer Detection: Insights from Consecutive Screening
Analysis of the Malmö Breast Tomosynthesis Screening Trial revealed lower cancer detection rates and invasive cancers after tomosynthesis, suggesting enhanced early detection potential, particularly for luminal A–like cancers.
- Open Access
- 7 December 2022
- Published by Wiley in Journal of Internal Medicine
- Vol. 293 (3) , 293-308
The complexity of kidney disease and diagnosing it – cystatin C, selective glomerular hypofiltration syndromes and proteome regulation
Estimation of kidney function is often part of daily clinical practice, mostly done by using the endogenous glomerular filtration rate (GFR)‐markers creatinine or cystatin C. A recommendation to use both markers in parallel in 2010 has resulted in new knowledge concerning the pathophysiology of kidney disorders by the identification of a new set of kidney disorders, selective glomerular hypofiltration syndromes. These syndromes, connected to strong increases in mortality and morbidity, are characterized by a selective reduction in the glomerular filtration of 5–30 kDa molecules, such as cystatin C, compared to the filtration of small molecules <1 kDa dominating the glomerular filtrate, for example water, urea and creatinine. At least two types of such disorders, shrunken or elongated pore syndrome, are possible according to the pore model for glomerular filtration. Selective glomerular hypofiltration syndromes are prevalent in investigated populations, and patients with these syndromes often display normal measured GFR or creatinine‐based GFR‐estimates. The syndromes are characterized by proteomic changes promoting the development of atherosclerosis, indicating antibodies and specific receptor‐blocking substances as possible new treatment modalities. Presently, the KDIGO guidelines for diagnosing kidney disorders do not recommend cystatin C as a general marker of kidney function and will therefore not allow the identification of a considerable number of patients with selective glomerular hypofiltration syndromes. Furthermore, as cystatin C is uninfluenced by muscle mass, diet or variations in tubular secretion and cystatin C‐based GFR‐estimation equations do not require controversial race or sex terms, it is obvious that cystatin C should be a part of future KDIGO guidelines.
- 7 December 2022
- Published by Wiley in Journal of Internal Medicine
- Vol. 293 (3) , 293-308
Open AccessThe complexity of kidney disease and diagnosing it – cystatin C, selective glomerular hypofiltration syndromes and proteome regulation
Estimation of kidney function is often part of daily clinical practice, mostly done by using the endogenous glomerular filtration rate (GFR)‐markers creatinine or cystatin C. A recommendation to use both markers in parallel in 2010 has resulted in new knowledge concerning the pathophysiology of kidney disorders by the identification of a new set of kidney disorders, selective glomerular hypofiltration syndromes. These syndromes, connected to strong increases in mortality and morbidity, are characterized by a selective reduction in the glomerular filtration of 5–30 kDa molecules, such as cystatin C, compared to the filtration of small molecules <1 kDa dominating the glomerular filtrate, for example water, urea and creatinine. At least two types of such disorders, shrunken or elongated pore syndrome, are possible according to the pore model for glomerular filtration. Selective glomerular hypofiltration syndromes are prevalent in investigated populations, and patients with these syndromes often display normal measured GFR or creatinine‐based GFR‐estimates. The syndromes are characterized by proteomic changes promoting the development of atherosclerosis, indicating antibodies and specific receptor‐blocking substances as possible new treatment modalities. Presently, the KDIGO guidelines for diagnosing kidney disorders do not recommend cystatin C as a general marker of kidney function and will therefore not allow the identification of a considerable number of patients with selective glomerular hypofiltration syndromes. Furthermore, as cystatin C is uninfluenced by muscle mass, diet or variations in tubular secretion and cystatin C‐based GFR‐estimation equations do not require controversial race or sex terms, it is obvious that cystatin C should be a part of future KDIGO guidelines.
- Open Access
- 7 December 2021
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 16 (1) , 1-8
Trapeziectomy for basal thumb osteoarthritis does not increase the risk of developing wrist osteoarthritis in the long term
Background: Symptomatic osteoarthritis of the basal joint of the thumb (trapeziometacarpal joint) is a common disabling condition mainly affecting women. It is frequently treated with complete removal of the trapezium with or without soft-tissue interposition. There is limited evidence about whether removal of the trapezium affects stability of the wrist joint and increases the risk of developing wrist osteoarthritis. The aim of this study was to evaluate the long-term prevalence of OA in wrists with previous trapeziectomy compared to wrists with intact trapezium. Methods: Patients treated with surgery for trapeziometacarpal osteoarthritis at one orthopedic department were invited 10–29 (mean 17) years postoperatively for bilateral radiographic examination. We included radiographs from 114 hands with trapeziectomy and 46 hands with intact trapezium; 38 patients had unilateral trapeziectomy and intact contralateral trapezium. The radiographs were blinded so that the intact trapezium or the trapezial space after trapeziectomy was not visible. The radiographs were then evaluated for radiocarpal/midcarpal osteoarthritis independently by two assessors using three different osteoarthritis grading systems, including the Kellgren–Lawrence classification. The patients rated their satisfaction with the function of each of their hands on a visual analog scale (VAS) from 0 to 100 (higher score better). Results: The prevalence of osteoarthritis ranged from 20 to 26%, mostly mild (Kellgren–Lawrence grade 1). The prevalence of osteoarthritis did not differ between wrists with previous trapeziectomy and those with intact trapezium, both in the whole cohort and in the subgroup of patients with unilateral trapeziectomy and intact contralateral trapezium. There was no significant difference in hand function VAS scores between hands with previous trapeziectomy and hands with intact trapezium in the whole cohort or in the subgroup. Conclusions: Removal of the trapezium as treatment for basal thumb osteoarthritis does not increase the risk of developing wrist osteoarthritis in the long term.
- 7 December 2021
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 16 (1) , 1-8
Open AccessTrapeziectomy for basal thumb osteoarthritis does not increase the risk of developing wrist osteoarthritis in the long term
Background: Symptomatic osteoarthritis of the basal joint of the thumb (trapeziometacarpal joint) is a common disabling condition mainly affecting women. It is frequently treated with complete removal of the trapezium with or without soft-tissue interposition. There is limited evidence about whether removal of the trapezium affects stability of the wrist joint and increases the risk of developing wrist osteoarthritis. The aim of this study was to evaluate the long-term prevalence of OA in wrists with previous trapeziectomy compared to wrists with intact trapezium. Methods: Patients treated with surgery for trapeziometacarpal osteoarthritis at one orthopedic department were invited 10–29 (mean 17) years postoperatively for bilateral radiographic examination. We included radiographs from 114 hands with trapeziectomy and 46 hands with intact trapezium; 38 patients had unilateral trapeziectomy and intact contralateral trapezium. The radiographs were blinded so that the intact trapezium or the trapezial space after trapeziectomy was not visible. The radiographs were then evaluated for radiocarpal/midcarpal osteoarthritis independently by two assessors using three different osteoarthritis grading systems, including the Kellgren–Lawrence classification. The patients rated their satisfaction with the function of each of their hands on a visual analog scale (VAS) from 0 to 100 (higher score better). Results: The prevalence of osteoarthritis ranged from 20 to 26%, mostly mild (Kellgren–Lawrence grade 1). The prevalence of osteoarthritis did not differ between wrists with previous trapeziectomy and those with intact trapezium, both in the whole cohort and in the subgroup of patients with unilateral trapeziectomy and intact contralateral trapezium. There was no significant difference in hand function VAS scores between hands with previous trapeziectomy and hands with intact trapezium in the whole cohort or in the subgroup. Conclusions: Removal of the trapezium as treatment for basal thumb osteoarthritis does not increase the risk of developing wrist osteoarthritis in the long term.
- Open Access
- 1 October 2021
- Published by Elsevier in The Breast
- Vol. 59, 16-26
Population-based mammography screening attendance in Sweden 2017–2018: A cross-sectional register study to assess the impact of sociodemographic factors
- 1 October 2021
- Published by Elsevier in The Breast
- Vol. 59, 16-26
Open AccessPopulation-based mammography screening attendance in Sweden 2017–2018: A cross-sectional register study to assess the impact of sociodemographic factors
- 1 June 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 299 (3) , 559-567
Interval Breast Cancer Rates and Tumor Characteristics in the Prospective Population-based Malmö Breast Tomosynthesis Screening Trial
Screening with one-view digital breast tomosynthesis in a prospective trial reduced the interval cancer rate compared with a contemporary control group screened with digital mammography. Background Interval cancer rates can be used to evaluate whether screening with digital breast tomosynthesis (DBT) contributes to a screening benefit. Purpose To compare interval cancer rates and t...
- 1 June 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 299 (3) , 559-567
Interval Breast Cancer Rates and Tumor Characteristics in the Prospective Population-based Malmö Breast Tomosynthesis Screening Trial
Screening with one-view digital breast tomosynthesis in a prospective trial reduced the interval cancer rate compared with a contemporary control group screened with digital mammography. Background Interval cancer rates can be used to evaluate whether screening with digital breast tomosynthesis (DBT) contributes to a screening benefit. Purpose To compare interval cancer rates and t...
- 1 May 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 299 (2) , 383-393
Development of MRI-defined Structural Tissue Damage after Anterior Cruciate Ligament Injury over 5 Years: The KANON Study
Young adults with acute anterior cruciate ligament injury showed no major difference in frequency of structural tissue damage on MRI scans at 2 and 5 years whether their injury was treated with rec... Background MRI is used to evaluate structural joint changes after anterior cruciate ligament (ACL) injury, but no long-term data are available for comparing different treatment approaches. Purpose ...
- 1 May 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 299 (2) , 383-393
Development of MRI-defined Structural Tissue Damage after Anterior Cruciate Ligament Injury over 5 Years: The KANON Study
Young adults with acute anterior cruciate ligament injury showed no major difference in frequency of structural tissue damage on MRI scans at 2 and 5 years whether their injury was treated with rec... Background MRI is used to evaluate structural joint changes after anterior cruciate ligament (ACL) injury, but no long-term data are available for comparing different treatment approaches. Purpose ...
- 24 July 2012
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 8 (34) , 8972-8980
Induced dye leakage by PAMAM G6 does not imply dendrimer entry into vesicle lumen
Dendrimers are polymers with unique properties that make them promising in a variety of applications such as potential drug and gene delivery systems. Polyamidoamine (PAMAM) dendrimers, in particular, have been widely investigated since they enter rapidly into cells. The entry mechanism, however, is still not yet fully clarified as both passive and active uptake have been proposed. In this work we focus on understanding passive uptake, for which simple cell model systems are used in order to ensure that only dendrimer–lipid interactions are probed. We developed protocols for investigating independently the effect of the dendrimer on lipid bilayer integrity, in terms of permeability of small dyes and effective dendrimer translocation. This was achieved by the use of membrane labeled giant unilamellar vesicles (GUVs) either containing Alexa 488 hydrazide in the vesicle lumen or FITC-labeled PAMAM G6 dendrimers. Vesicle integrity and dendrimer–membrane binding were then assessed by fluorescence microscopy. The importance of membrane fluidity and charge was investigated using GUVs composed of various lipid compositions. A quartz crystal microbalance with dissipation was used to probe the effect of dendrimers on the rigidity of vesicle layers. The results indicate that PAMAM dendrimers can locally alter the membrane properties. An increased bilayer permeability towards soluble small dyes but no effective translocation, where PAMAM dendrimers could dissociate from the lipid membrane into the vesicle lumen, was observed. To our knowledge this is the first time it is shown that PAMAM G6 dendrimer does not effectively translocate the lipid bilayer although it readily interacts with the model membrane, regardless of lipid membrane properties. However, bilayer charge and fluidity modulate the dendrimer interaction in agreement with previous reports. The results clearly highlight the importance of the choice of the model system when investigating nanoparticles interaction with lipid membranes.
- 24 July 2012
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 8 (34) , 8972-8980
Induced dye leakage by PAMAM G6 does not imply dendrimer entry into vesicle lumen
Dendrimers are polymers with unique properties that make them promising in a variety of applications such as potential drug and gene delivery systems. Polyamidoamine (PAMAM) dendrimers, in particular, have been widely investigated since they enter rapidly into cells. The entry mechanism, however, is still not yet fully clarified as both passive and active uptake have been proposed. In this work we focus on understanding passive uptake, for which simple cell model systems are used in order to ensure that only dendrimer–lipid interactions are probed. We developed protocols for investigating independently the effect of the dendrimer on lipid bilayer integrity, in terms of permeability of small dyes and effective dendrimer translocation. This was achieved by the use of membrane labeled giant unilamellar vesicles (GUVs) either containing Alexa 488 hydrazide in the vesicle lumen or FITC-labeled PAMAM G6 dendrimers. Vesicle integrity and dendrimer–membrane binding were then assessed by fluorescence microscopy. The importance of membrane fluidity and charge was investigated using GUVs composed of various lipid compositions. A quartz crystal microbalance with dissipation was used to probe the effect of dendrimers on the rigidity of vesicle layers. The results indicate that PAMAM dendrimers can locally alter the membrane properties. An increased bilayer permeability towards soluble small dyes but no effective translocation, where PAMAM dendrimers could dissociate from the lipid membrane into the vesicle lumen, was observed. To our knowledge this is the first time it is shown that PAMAM G6 dendrimer does not effectively translocate the lipid bilayer although it readily interacts with the model membrane, regardless of lipid membrane properties. However, bilayer charge and fluidity modulate the dendrimer interaction in agreement with previous reports. The results clearly highlight the importance of the choice of the model system when investigating nanoparticles interaction with lipid membranes.